Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Healios KK ( (JP:4593) ) is now available.
Healios K.K. has agreed to supply human bone marrow-derived somatic stem cell culture supernatant as a raw material for future cosmetics products to be marketed in South Korea by JENECELL, a South Korean subsidiary of Alfresa Corporation. The initial order, valued at 144 million yen, will be shipped in stages starting July 2026, with both companies aligning on expected shipment volume and timing for subsequent orders.
Healios plans to begin booking revenue from this agreement in the third quarter of its fiscal year ending December 2026, recognizing sales upon each delivery to JENECELL. The deal extends Healios’s stem cell technology into the premium skincare and cosmetics market, potentially diversifying its revenue base beyond therapeutics while reinforcing ties with the Alfresa group, a major player in pharmaceutical distribution and advanced healthcare products in Japan and South Korea.
The most recent analyst rating on (JP:4593) stock is a Hold with a Yen366.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
More about Healios KK
Healios K.K. is a Japanese clinical-stage biotechnology company focused on regenerative medicine, leveraging somatic stem cells and induced pluripotent stem cells to develop therapies for diseases with limited treatment options. The Tokyo-listed firm is advancing pipeline candidates such as HLCM051 for ARDS, trauma and ischemic stroke, and HLCN061, a gene-modified NK cell therapy for solid tumors, supported by scalable 3D bioreactor manufacturing platforms.
Founded in 2011 and listed on the Tokyo Stock Exchange Growth market since 2015 under code 4593, Healios has built proprietary global platforms, including a gene-edited “universal donor” iPSC line, to address unmet needs in immuno-oncology, ophthalmology, liver diseases and other severe conditions. The company positions itself as a pioneer in Japan’s regenerative medicine sector, aiming to commercialize next-generation cell-based treatments internationally.
Average Trading Volume: 3,581,450
Technical Sentiment Signal: Hold
Current Market Cap: Yen51.71B
Find detailed analytics on 4593 stock on TipRanks’ Stock Analysis page.